Artykuły udostępnione publicznie: - Peter MullenWięcej informacji
Niedostępne w żadnym miejscu: 2
New strategies for targeting the hypoxic tumour microenvironment in breast cancer
C Ward, SP Langdon, P Mullen, AL Harris, DJ Harrison, CT Supuran, ...
Cancer treatment reviews 39 (2), 171-179, 2013
Upoważnienia: Cancer Research UK, UK Medical Research Council
Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy
D Faratian, IH Um, DS Wilson, P Mullen, SP Langdon, DJ Harrison
European Journal of Cancer 47 (9), 1420-1431, 2011
Upoważnienia: Cancer Research UK
Dostępne w jakimś miejscu: 17
Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells
F Hochgräfe, L Zhang, SA O'Toole, BC Browne, M Pinese, A Porta Cubas, ...
Cancer research 70 (22), 9391-9401, 2010
Upoważnienia: Cancer Research UK
Novel flavonoids as anti-cancer agents: mechanisms of action and promise for their potential application in breast cancer
C Martinez-Perez, C Ward, G Cook, P Mullen, D McPhail, DJ Harrison, ...
Biochemical Society Transactions 42 (4), 1017-1023, 2014
Upoważnienia: UK Biotechnology and Biological Sciences Research Council
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models
C Ward, J Meehan, P Mullen, C Supuran, JM Dixon, JS Thomas, ...
Oncotarget 6 (28), 24856, 2015
Upoważnienia: UK Medical Research Council
Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo
K Morgan, AJ Stewart, N Miller, P Mullen, M Muir, M Dodds, F Medda, ...
Cancer research 68 (15), 6331-6340, 2008
Upoważnienia: Cancer Research UK
Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy
D Faratian, AH Sims, P Mullen, C Kay, IH Um, SP Langdon, DJ Harrison
PloS one 6 (8), e23772, 2011
Upoważnienia: Cancer Research UK
Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells
J Meehan, C Ward, A Turnbull, J Bukowski-Wills, AJ Finch, EJ Jarman, ...
Oncotarget 8 (26), 42857, 2017
Upoważnienia: UK Engineering and Physical Sciences Research Council, UK Medical Research …
Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models
C Martínez-Pérez, C Ward, AK Turnbull, P Mullen, G Cook, J Meehan, ...
British Journal of Cancer 114 (8), 905-916, 2016
Upoważnienia: UK Medical Research Council
Carbonic anhydrase 9 expression increases with vascular endothelial growth factor–targeted therapy and is predictive of outcome in metastatic clear cell renal cancer
GD Stewart, FC O’Mahony, A Laird, S Rashid, SA Martin, L Eory, ...
European urology 66 (5), 956-963, 2014
Upoważnienia: Cancer Research UK, UK Medical Research Council, European Commission
Diversity of matriptase expression level and function in breast cancer
A Welman, D Sproul, P Mullen, M Muir, AR Kinnaird, DJ Harrison, ...
PLoS One 7 (4), e34182, 2012
Upoważnienia: Cancer Research UK
Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer
GD Stewart, FC O'Mahony, A Laird, L Eory, ALR Lubbock, A Mackay, ...
Clinical Cancer Research 21 (18), 4212-4223, 2015
Upoważnienia: Cancer Research UK, Chief Scientist Office, Scottish Executive, UK Medical …
The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers
FC O'Mahony, J Nanda, A Laird, P Mullen, H Caldwell, IM Overton, L Eory, ...
Journal of visualized experiments: JoVE, 50221, 2013
Upoważnienia: Cancer Research UK
Total synthesis of dehaloperophoramidine using a highly diastereoselective Hosomi–Sakurai reaction
RP Wilkie, AR Neal, CA Johnston, N Voute, CS Lancefield, MD Stell, ...
Chemical Communications 52 (71), 10747-10750, 2016
Upoważnienia: UK Engineering and Physical Sciences Research Council
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031
A Sarr, J Bré, IH Um, TH Chan, P Mullen, DJ Harrison, PA Reynolds
Scientific reports 9 (1), 7643, 2019
Upoważnienia: UK Biotechnology and Biological Sciences Research Council, UK Medical …
The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent
J Bré, AL Dickson, OJ Read, Y Zhang, FG McKissock, P Mullen, P Tang, ...
Cancer Chemotherapy and Pharmacology 91 (5), 401-412, 2023
Upoważnienia: Wellcome Trust
Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer
ALR Lubbock, GD Stewart, FC O’Mahony, A Laird, P Mullen, M O’Donnell, ...
BMC medicine 15, 1-12, 2017
Upoważnienia: Cancer Research UK, Chief Scientist Office, Scottish Executive, UK Medical …
Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model
KM Moore, V Cerqueira, KG MacLeod, P Mullen, RL Hayward, S Green, ...
Exploration of targeted anti-tumor therapy 3 (1), 97, 2022
Upoważnienia: Cancer Research UK
Long-read Spatial Transcriptomic Profiling of Patient-derived ccRCC Tumoroids Reveals Heterogeneity in Isoform and Gene Expression
M Elshani, H Abdullah, Y Zhang, A Laird, P Mullen, DJ Harrison
bioRxiv, 2024.10. 16.618643, 2024
Upoważnienia: UK Biotechnology and Biological Sciences Research Council, European Commission
Informacje na temat publikacji i finansowania automatycznie określa program komputerowy